Are you over 18 and want to see adult content?
More Annotations
A complete backup of projetofauna.wordpress.com
Are you over 18 and want to see adult content?
A complete backup of rightmeowornever.com
Are you over 18 and want to see adult content?
A complete backup of geohackweek.github.io
Are you over 18 and want to see adult content?
A complete backup of thefloaterdoctor.com
Are you over 18 and want to see adult content?
A complete backup of lowcostliving.co.uk
Are you over 18 and want to see adult content?
A complete backup of kertbirodalom.hu
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of www.polskieradio24.pl/5/1222/Artykul/2459867
Are you over 18 and want to see adult content?
Text
more.
PIK3CA E545K
PIK3CA is altered in 13.98% of malignant solid tumor patients with PIK3CA E545K present in 2.86% of all malignant solid tumor patients . PIK3CA E545K is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA E545K and malignant solid tumor asinclusion
MODIFIED FOLFOX6 REGIMEN Modified folfox6 regimen has been investigated in 26 clinical trials, of which 22 are open and 4 are closed. NRAS Q61K - MY CANCER GENOME Biomarker-Directed Therapies. NRAS Q61K is a predictive biomarker for use of binimetinib, cetuximab, and panitumumab in patients. Of the therapies with NRAS Q61K as a predictive biomarker, 2 are FDA-approved and 3 have NCCN guidelines in at least one clinical setting. POLD1 - MY CANCER GENOME Polymerase (DNA directed), delta 1, catalytic subunit (POLD1) is a gene that encodes a subunit of DNA polymerase delta, a protein complex that plays a critical role in DNA replication and repair. Missense mutations, synonymous mutations, frameshift deletions, and nonsense mutations are observed in cancers such as colon cancer, skin cancer,and
KRAS G12A - MY CANCER GENOME Biomarker-Directed Therapies. KRAS G12A is a predictive biomarker for use of afatinib, dacomitinib, erlotinib, gefitinib, osimertinib, cetuximab, and panitumumab in patients. Of the therapies with KRAS G12A as a predictive biomarker, 2 are FDA-approved and 7 have NCCN guidelines in at least one clinical setting.CCND1 MUTATION
CCND1 Mutation is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CCND1 Mutation and breast carcinoma as inclusion criteria, 1 is phase 2 (0 open) . Germ Cell Tumor +. CCND1 is altered in 0.14% of germ cell tumor patients .ARID1A MUTATION
ARID1A Mutation is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ARID1A Mutation and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) . Uveal Melanoma +.ERBB2 S310F
ERBB2 S310F is an inclusion criterion in 3 clinical trials for breast carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 S310F and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) . UrethralCarcinoma +.
BERZOSERTIB
ATR kinase inhibitor VX-970 selectively inhibits ATR kinase activity and prevents ATR-mediated signaling in the ATR-checkpoint kinase 1 (Chk1) signaling pathway. This prevents DNA damage checkpoint activation, disrupts DNA damage repair, and induces tumor cell apoptosis. In addition, VX-970 sensitizes tumor cells to chemo- andradiotherapy.
HOME - MY CANCER GENOMECLINICAL TRIALSDISEASESBIOMARKERSDRUGSPATHWAYSCONTRIBUTORS My Cancer Genome contains information on the clinical impact of molecular biomarkers in cancer-related genes, proteins, and other biomarker types on the use of anticancer therapies in cancer. This information is derived from FDA labels, NCCN and other professional society guidelines, clinical trials, peer-reviewed publications, andmore.
PIK3CA E545K
PIK3CA is altered in 13.98% of malignant solid tumor patients with PIK3CA E545K present in 2.86% of all malignant solid tumor patients . PIK3CA E545K is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA E545K and malignant solid tumor asinclusion
MODIFIED FOLFOX6 REGIMEN Modified folfox6 regimen has been investigated in 26 clinical trials, of which 22 are open and 4 are closed. NRAS Q61K - MY CANCER GENOME Biomarker-Directed Therapies. NRAS Q61K is a predictive biomarker for use of binimetinib, cetuximab, and panitumumab in patients. Of the therapies with NRAS Q61K as a predictive biomarker, 2 are FDA-approved and 3 have NCCN guidelines in at least one clinical setting. POLD1 - MY CANCER GENOME Polymerase (DNA directed), delta 1, catalytic subunit (POLD1) is a gene that encodes a subunit of DNA polymerase delta, a protein complex that plays a critical role in DNA replication and repair. Missense mutations, synonymous mutations, frameshift deletions, and nonsense mutations are observed in cancers such as colon cancer, skin cancer,and
KRAS G12A - MY CANCER GENOME Biomarker-Directed Therapies. KRAS G12A is a predictive biomarker for use of afatinib, dacomitinib, erlotinib, gefitinib, osimertinib, cetuximab, and panitumumab in patients. Of the therapies with KRAS G12A as a predictive biomarker, 2 are FDA-approved and 7 have NCCN guidelines in at least one clinical setting.CCND1 MUTATION
CCND1 Mutation is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CCND1 Mutation and breast carcinoma as inclusion criteria, 1 is phase 2 (0 open) . Germ Cell Tumor +. CCND1 is altered in 0.14% of germ cell tumor patients .ARID1A MUTATION
ARID1A Mutation is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ARID1A Mutation and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) . Uveal Melanoma +.ERBB2 S310F
ERBB2 S310F is an inclusion criterion in 3 clinical trials for breast carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 S310F and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) . UrethralCarcinoma +.
BERZOSERTIB
ATR kinase inhibitor VX-970 selectively inhibits ATR kinase activity and prevents ATR-mediated signaling in the ATR-checkpoint kinase 1 (Chk1) signaling pathway. This prevents DNA damage checkpoint activation, disrupts DNA damage repair, and induces tumor cell apoptosis. In addition, VX-970 sensitizes tumor cells to chemo- andradiotherapy.
EGFR L858R - MY CANCER GENOME EGFR L858R is a predictive biomarker for use of afatinib, erlotinib, gefitinib, osimertinib, capmatinib, crizotinib, dacomitinib, cetuximab, and pembrolizumab in patients. Of the therapies with EGFR L858R as a predictive biomarker, 6 are FDA-approved and 8 have NCCN guidelines in at least one clinical setting. CHEK1 - MY CANCER GENOME CHEK1 is an inclusion criterion in 3 clinical trials for soft tissue sarcoma, of which 2 are open and 1 is closed. Of the trials that contain CHEK1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) . High Grade Ovarian Serous Adenocarcinoma +. AZD5305 - MY CANCER GENOME An orally bioavailable inhibitor of the nuclear enzyme poly (ADP-ribose) polymerase (PARP), with potential chemo/radiosensitizing and antineoplastic activities. Upon administration, PARP inhibitor AZD5305 selectively targets and binds to PARP and prevents PARP-mediated DNA repair of single-strand DNA breaks via the base-excision repair pathway.NBN MUTATION
NBN Mutation is an inclusion criterion in 4 clinical trials for gastric adenocarcinoma, of which 4 are open and 0 are closed. Of the trials that contain NBN Mutation and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (3 open) . Pancreatic Carcinoma +. IDH1 R132C - MY CANCER GENOME IDH1 is altered in 24.88% of glioma patients with IDH1 R132C present in 1.4% of all glioma patients . IDH1 R132C is an inclusion criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 R132C and glioma as inclusion criteria, 1 is phase 2 (1 open) . CDKN2A - MY CANCER GENOME CDKN2A is an inclusion criterion in 1 clinical trial for germ cell tumor, of which 0 are open and 1 is closed. Of the trial that contains CDKN2A status and germ cell tumor as inclusion criteria, 1 is phase 2 (0 open) . Appendix Carcinoma +. CDKN2A is altered in 0.66% of appendix carcinoma patients .ERBB2 S310F
ERBB2 S310F is an inclusion criterion in 3 clinical trials for breast carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 S310F and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) . UrethralCarcinoma +.
PALB2 MUTATION
PALB2 Mutation is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PALB2 Mutation and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) . Non-Hodgkin Lymphoma +. EGFR EXON 21 MUTATION EGFR Exon 21 Mutation is an inclusion criterion in 8 clinical trials for non-small cell lung carcinoma, of which 8 are open and 0 are closed. Of the trials that contain EGFR Exon 21 Mutation and non-small cell lung carcinoma as inclusion criteria, 4 are phase 2 (4 open),ERBB2 R678Q
ERBB2 is altered in 1.84% of glioblastoma patients . ERBB2 R678Q is an inclusion criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 R678Q and glioblastoma as inclusion criteria, 1 is phase 2 (1 open) . WHO Grade III Glioma +. HOME - MY CANCER GENOMECLINICAL TRIALSDISEASESBIOMARKERSDRUGSPATHWAYSCONTRIBUTORS My Cancer Genome contains information on the clinical impact of molecular biomarkers in cancer-related genes, proteins, and other biomarker types on the use of anticancer therapies in cancer. This information is derived from FDA labels, NCCN and other professional society guidelines, clinical trials, peer-reviewed publications, andmore.
PIK3CA E545K
PIK3CA is altered in 13.98% of malignant solid tumor patients with PIK3CA E545K present in 2.86% of all malignant solid tumor patients . PIK3CA E545K is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA E545K and malignant solid tumor asinclusion
MODIFIED FOLFOX6 REGIMEN Modified folfox6 regimen has been investigated in 26 clinical trials, of which 22 are open and 4 are closed. NRAS Q61K - MY CANCER GENOME Biomarker-Directed Therapies. NRAS Q61K is a predictive biomarker for use of binimetinib, cetuximab, and panitumumab in patients. Of the therapies with NRAS Q61K as a predictive biomarker, 2 are FDA-approved and 3 have NCCN guidelines in at least one clinical setting. POLD1 - MY CANCER GENOME Polymerase (DNA directed), delta 1, catalytic subunit (POLD1) is a gene that encodes a subunit of DNA polymerase delta, a protein complex that plays a critical role in DNA replication and repair. Missense mutations, synonymous mutations, frameshift deletions, and nonsense mutations are observed in cancers such as colon cancer, skin cancer,and
KRAS G12A - MY CANCER GENOME Biomarker-Directed Therapies. KRAS G12A is a predictive biomarker for use of afatinib, dacomitinib, erlotinib, gefitinib, osimertinib, cetuximab, and panitumumab in patients. Of the therapies with KRAS G12A as a predictive biomarker, 2 are FDA-approved and 7 have NCCN guidelines in at least one clinical setting.CCND1 MUTATION
CCND1 Mutation is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CCND1 Mutation and breast carcinoma as inclusion criteria, 1 is phase 2 (0 open) . Germ Cell Tumor +. CCND1 is altered in 0.14% of germ cell tumor patients .ARID1A MUTATION
ARID1A Mutation is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ARID1A Mutation and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) . Uveal Melanoma +.ERBB2 S310F
ERBB2 S310F is an inclusion criterion in 3 clinical trials for breast carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 S310F and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) . UrethralCarcinoma +.
BERZOSERTIB
ATR kinase inhibitor VX-970 selectively inhibits ATR kinase activity and prevents ATR-mediated signaling in the ATR-checkpoint kinase 1 (Chk1) signaling pathway. This prevents DNA damage checkpoint activation, disrupts DNA damage repair, and induces tumor cell apoptosis. In addition, VX-970 sensitizes tumor cells to chemo- andradiotherapy.
HOME - MY CANCER GENOMECLINICAL TRIALSDISEASESBIOMARKERSDRUGSPATHWAYSCONTRIBUTORS My Cancer Genome contains information on the clinical impact of molecular biomarkers in cancer-related genes, proteins, and other biomarker types on the use of anticancer therapies in cancer. This information is derived from FDA labels, NCCN and other professional society guidelines, clinical trials, peer-reviewed publications, andmore.
PIK3CA E545K
PIK3CA is altered in 13.98% of malignant solid tumor patients with PIK3CA E545K present in 2.86% of all malignant solid tumor patients . PIK3CA E545K is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA E545K and malignant solid tumor asinclusion
MODIFIED FOLFOX6 REGIMEN Modified folfox6 regimen has been investigated in 26 clinical trials, of which 22 are open and 4 are closed. NRAS Q61K - MY CANCER GENOME Biomarker-Directed Therapies. NRAS Q61K is a predictive biomarker for use of binimetinib, cetuximab, and panitumumab in patients. Of the therapies with NRAS Q61K as a predictive biomarker, 2 are FDA-approved and 3 have NCCN guidelines in at least one clinical setting. POLD1 - MY CANCER GENOME Polymerase (DNA directed), delta 1, catalytic subunit (POLD1) is a gene that encodes a subunit of DNA polymerase delta, a protein complex that plays a critical role in DNA replication and repair. Missense mutations, synonymous mutations, frameshift deletions, and nonsense mutations are observed in cancers such as colon cancer, skin cancer,and
KRAS G12A - MY CANCER GENOME Biomarker-Directed Therapies. KRAS G12A is a predictive biomarker for use of afatinib, dacomitinib, erlotinib, gefitinib, osimertinib, cetuximab, and panitumumab in patients. Of the therapies with KRAS G12A as a predictive biomarker, 2 are FDA-approved and 7 have NCCN guidelines in at least one clinical setting.CCND1 MUTATION
CCND1 Mutation is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CCND1 Mutation and breast carcinoma as inclusion criteria, 1 is phase 2 (0 open) . Germ Cell Tumor +. CCND1 is altered in 0.14% of germ cell tumor patients .ARID1A MUTATION
ARID1A Mutation is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ARID1A Mutation and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) . Uveal Melanoma +.ERBB2 S310F
ERBB2 S310F is an inclusion criterion in 3 clinical trials for breast carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 S310F and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) . UrethralCarcinoma +.
BERZOSERTIB
ATR kinase inhibitor VX-970 selectively inhibits ATR kinase activity and prevents ATR-mediated signaling in the ATR-checkpoint kinase 1 (Chk1) signaling pathway. This prevents DNA damage checkpoint activation, disrupts DNA damage repair, and induces tumor cell apoptosis. In addition, VX-970 sensitizes tumor cells to chemo- andradiotherapy.
EGFR L858R - MY CANCER GENOME EGFR L858R is a predictive biomarker for use of afatinib, erlotinib, gefitinib, osimertinib, capmatinib, crizotinib, dacomitinib, cetuximab, and pembrolizumab in patients. Of the therapies with EGFR L858R as a predictive biomarker, 6 are FDA-approved and 8 have NCCN guidelines in at least one clinical setting. CHEK1 - MY CANCER GENOME CHEK1 is an inclusion criterion in 3 clinical trials for soft tissue sarcoma, of which 2 are open and 1 is closed. Of the trials that contain CHEK1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) . High Grade Ovarian Serous Adenocarcinoma +. AZD5305 - MY CANCER GENOME An orally bioavailable inhibitor of the nuclear enzyme poly (ADP-ribose) polymerase (PARP), with potential chemo/radiosensitizing and antineoplastic activities. Upon administration, PARP inhibitor AZD5305 selectively targets and binds to PARP and prevents PARP-mediated DNA repair of single-strand DNA breaks via the base-excision repair pathway.NBN MUTATION
NBN Mutation is an inclusion criterion in 4 clinical trials for gastric adenocarcinoma, of which 4 are open and 0 are closed. Of the trials that contain NBN Mutation and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (3 open) . Pancreatic Carcinoma +. IDH1 R132C - MY CANCER GENOME IDH1 is altered in 24.88% of glioma patients with IDH1 R132C present in 1.4% of all glioma patients . IDH1 R132C is an inclusion criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 R132C and glioma as inclusion criteria, 1 is phase 2 (1 open) . CDKN2A - MY CANCER GENOME CDKN2A is an inclusion criterion in 1 clinical trial for germ cell tumor, of which 0 are open and 1 is closed. Of the trial that contains CDKN2A status and germ cell tumor as inclusion criteria, 1 is phase 2 (0 open) . Appendix Carcinoma +. CDKN2A is altered in 0.66% of appendix carcinoma patients .ERBB2 S310F
ERBB2 S310F is an inclusion criterion in 3 clinical trials for breast carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 S310F and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) . UrethralCarcinoma +.
PALB2 MUTATION
PALB2 Mutation is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PALB2 Mutation and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) . Non-Hodgkin Lymphoma +. EGFR EXON 21 MUTATION EGFR Exon 21 Mutation is an inclusion criterion in 8 clinical trials for non-small cell lung carcinoma, of which 8 are open and 0 are closed. Of the trials that contain EGFR Exon 21 Mutation and non-small cell lung carcinoma as inclusion criteria, 4 are phase 2 (4 open),ERBB2 R678Q
ERBB2 is altered in 1.84% of glioblastoma patients . ERBB2 R678Q is an inclusion criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 R678Q and glioblastoma as inclusion criteria, 1 is phase 2 (1 open) . WHO Grade III Glioma +.CLINICAL TRIALS
DISEASES
BIOMARKERS
DRUGS
PATHWAYS
CLINICAL IMPLICATIONS OF MOLECULAR BIOMARKERS My Cancer Genome contains information on the clinical impact of molecular biomarkers in cancer-related genes, proteins, and other biomarker types on the use of anticancer therapies in cancer. This information is derived from FDA labels, NCCN and other professional society guidelines, clinical trials, peer-reviewed publications, andmore.
Learn About My Cancer Genome MOLECULAR MEDICINE RESOURCESTARGETED THERAPIES
Types, classification, and naming; FDA approved therapiesLearn More
MOLECULAR TESTING
Biomarkers can be detected using multiple types of testsLearn More
MOLECULAR TUMOR BOARD Molecular tumor board for patients with somatic or germline mutationsLearn More
GLOSSARY
Understand terms related to precision medicineLearn More
ABOUT
Home
What Is My Cancer Genome? My Cancer Genome Data Sources Legal Policies & Licensing Letter from the EditorsAcknowledgments
About GenomOncology
Contributors
How to Give to My Cancer GenomeMOLECULAR MEDICINE
Types of Molecular Tumor TestingCirculating DNA
Detecting Gene Alterations in CancersGlossary
Targeted Therapies
Molecular Tumor BoardCONTENT TYPES
Clinical Trials
Diseases
Biomarkers
Drugs
Pathways
My Cancer Genome is managed by the Vanderbilt-Ingram Cancer Center Copyright © 2010 - 2017 MY CANCER GENOMEDetails
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0